SIGA
SIGA Technologies, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.29
+1.86%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 53.7M | 94.6M | 138.7M | 139.9M | 110.8M |
| Cost of Revenue | 24.5M | 29.7M | 31.3M | 17.8M | 10.4M |
| Gross Profit | 29.2M | 64.9M | 107.4M | 122.1M | 100.3M |
| Operating Expenses | |||||
| R&D Expense | 2704.7B | 6.5M | 12.3M | 16.4M | 22.5M |
| SG&A Expense | 4673.0B | 3.1M | 25.1M | 22.0M | 35.1M |
| General & Admin Expense | 5.1M | 3.1M | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (7377.7B) | 31.5M | — | — | — |
| Total Operating Expenses | 40.3M | 41.2M | 37.4M | 38.5M | 57.6M |
| Cost and Expenses | 64.8M | 70.9M | 68.7M | 56.3M | 68.1M |
| Operating Income (EBIT) | (11.1M) | 23.7M | 70.0M | 83.6M | 42.7M |
| Non-Operating | |||||
| Interest Income | 2.8M | 6.7M | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 2.8M | 6.7M | — | — | — |
| Other Non-Op Income/Expense | 5.6M | 6.7M | 6.1M | 4.2M | 1.4M |
| Non-Operating Income (excl Interest) | (5.6M) | (6.7M) | (6.1M) | (4.2M) | (1.4M) |
| EBT (Pre-Tax Income) | (5.5M) | 30.4M | 76.1M | 87.8M | 44.1M |
| Income Tax Expense | (2.7M) | 7.1M | 16.9M | 19.7M | 10.2M |
| Bottom Line | |||||
| Net Income | (2.8M) | 23.3M | 59.2M | 68.1M | 33.9M |
| Earnings from Cont. Ops | (2.8M) | 23.3M | 59.2M | 68.1M | 33.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (2.8M) | 23.3M | 59.2M | 68.1M | 33.5M |
| Per Share | |||||
| Basic EPS | ($0.04) | $0.33 | $0.83 | $0.95 | $0.46 |
| Diluted EPS | ($0.04) | $0.33 | $0.83 | $0.95 | $0.46 |
| Revenue Per Share | $0.75 | $1.32 | $1.95 | $1.96 | $1.52 |
| Shares | |||||
| Basic Shares Outstanding | 71.8M | 71.6M | 71.3M | 71.4M | 72.9M |
| Diluted Shares Outstanding | 71.9M | 71.6M | 71.8M | 71.7M | 73.5M |
| Profitability Metrics | |||||
| EBITDA | (4.9M) | 31.0M | 76.6M | 88.3M | 44.7M |
| D&A | 590.5K | 562.6K | 538.4K | 538.3K | 517.6K |
| EBIT | (5.5M) | 30.4M | 76.1M | 87.8M | 44.1M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026